Aqilion initiates collaboration with Immunscape

Aqilion searches for early innovative pharmaceutical projects thatare based on solid research resting on a firm biological foundation and offering both clinical relevance and patient benefit. Immunscape has developed innovative molecules…

PULS changes its name to AQILION AB

Today the company Partners för Utvecklingsinvesteringar inom Life Science, P.U.L.S. AB is changing its name to AQILION AB. The name change marks a new phase in the development of the company, with a new strategy and identity. The decision…

PULS byter namn till AQILION AB

Idag byter bolaget Partners för Utvecklingsinvesteringar inom Life Science, P.U.L.S. AB namn till AQILION AB. Namnbytet markerar en ny fas i bolagets utveckling med en ny strategi och identitet. Beslutet togs formellt på en extra bolagsstämma…

PULS project company Laccure ends collaboration with Combe and continues the commercialization process in-house

Combe has announced that it is terminating the license agreement because the company has changed its priorities and strategy for its development projects. Laccure will take the product back and continue to pursue development toward commercialization…